Pablo J. Cagnoni - Jan 29, 2023 Form 4 Insider Report for Rubius Therapeutics, Inc. (RUBY)

Role: Director
Signature: /s/ Jennifer Kamocsay, attorney-in-fact
Stock symbol: RUBY
Transactions as of: Jan 29, 2023
Transactions value $: -$1,745
Form type: 4
Date filed: 1/31/2023, 08:51 PM
Previous filing: Jun 22, 2022
Next filing: Feb 1, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RUBY	Common Stock	Options Exercise		+21.3K	+59.83%		56.8K	Jan 29, 2023	Direct	F1
transaction	RUBY	Common Stock	Options Exercise		+25K	+44.04%		81.8K	Jan 31, 2023	Direct	F1
transaction	RUBY	Common Stock	Sale	-$1.74K	-7.24K	-8.85%	$0.24^*	74.5K	Jan 31, 2023	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RUBY	Restricted Stock Units	Options Exercise	$0	-21.3K	-33.33%	$0.00	42.5K	Jan 29, 2023	Common Stock	21.3K		Direct	F1, F4
transaction	RUBY	Restricted Stock Units	Options Exercise	$0	-25K	-25%	$0.00	75K	Jan 31, 2023	Common Stock	25K		Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.26, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4	The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022.
F5	The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney